Login to Your Account

Regeneron finds ally in Teva with potential $710M pain deal

By Marie Powers
News Editor

Tuesday, September 20, 2016

Regeneron Pharmaceuticals Inc. snagged Teva Pharmaceutical Industries Ltd. as its latest collaborator in a global deal on lead pain asset fasinumab, a NGF antibody in phase III studies for OA and phase II studies for chronic low back pain.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription